Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma.

Autor: Hwang GH; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts., Pazyra-Murphy MF; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Stopka SA; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., DiPiazza M; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Sutter N; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Brigham Young University-Hawaii, Kulanui St, Hawaii., Gero TW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Volkert A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ombelets L; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dittemore G; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Rees MG; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Ronan MM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Roth JA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Agar NYR; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Segal RA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Cancer research [Cancer Res] 2024 Mar 15; Vol. 84 (6), pp. 872-886.

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.

Autor: To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; College of Pharmacy, Korea University, Sejong, Korea., Feng WW; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Shin BH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Heppner DE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Chemistry, University at Buffalo, Buffalo, NY, USA., Rana JK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Poitras MJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kobayashi Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan., Wahid K; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Kurppa KJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Gero TW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Cameron MD; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Mushajiang M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Xu C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Zhang Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. michael_eck@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. michael_eck@dfci.harvard.edu., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Medicinal Chemistry and Department of Chemistry and Systems Biology, Stanford University, Stanford, CA, USA. nathanael_gray@dfci.harvard.edu., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. pasi_janne@dfci.harvard.edu.

Publikováno v: Nature cancer [Nat Cancer] 2022 Apr; Vol. 3 (4), pp. 402-417. Date of Electronic Publication: 2022 Apr 14.